Effect of the copayment reduction system on accessibility to orphan drugs in South Korea

References

• Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020 Feb 1;28(2):165–173.
   PubMed Web of Science ®Google Scholar
• Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. 2015 Jul;119(7):964–979.
   PubMed Web of Science ®Google Scholar
• Boycott KM, Vanstone MR, Bulman DE, et al. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet. 2013 Oct 1;14(10):681–691.
   PubMed Web of Science ®Google Scholar
• Song P, Gao J, Inagaki Y, et al. Rare diseases, orphan drugs, and their regulation in Asia: current status and future perspectives. Intractable Rare Dis Res. 2012 Feb 1;1(1):3–9.
   PubMedGoogle Scholar
• Gammie T, Lu CY, Babar ZU. Access to Orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PLoS One. 2015;10(10):e0140002.
   PubMed Web of Science ®Google Scholar
• He J, Song P, Kang Q, et al. Overview on social security system of rare diseases in China. Biosci Trends. 2019 Sep 17;13(4):314–323.
   PubMed Web of Science ®Google Scholar
• Huang YJ, Chao WY, Wang CC, et al. Orphan drug development: the impact of regulatory and reimbursement frameworks. Drug Discov Today. 2022 Jun;27(6):1724–1732.
   PubMed Web of Science ®Google Scholar
• Chan AYL, Chan VKY, Olsson S, et al. Access and unmet needs of Orphan drugs in 194 countries and 6 areas: a global policy review with content analysis. Value Health. 2020 Dec;23(12):1580–1591.
   PubMed Web of Science ®Google Scholar
• Ghiasvand H, Barnish MS, Moradi T, et al. Making orphan drugs and services available and accessible for people who live with rare diseases: what has been done? a systematic scoping review. Expert Opin Orphan Drugs. 2022 Dec 2;10(1):55–64.
   Web of Science ®Google Scholar
• Czech M, Baran-Kooiker A, Atikeler K, et al. A review of rare disease policies and orphan drug reimbursement systems in 12 Eurasian countries. Front Public Health. 2020;7:416.
   PubMed Web of Science ®Google Scholar
• Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011 Jun 17;6(1):42.
   PubMedGoogle Scholar
• Zimmermann BM, Eichinger J, Baumgartner MR. A systematic review of moral reasons on orphan drug reimbursement. Orphanet J Rare Dis. 2021 Jun 30;16(1):292.
   PubMed Web of Science ®Google Scholar
• Sawakami T. Current status of specific pediatric chronic diseases in Japan: national measures, disease types, treatment availability, copayment assistance, and research. Intractable Rare Dis Res. 2021 Nov;10(4):283–287.
   PubMed Web of Science ®Google Scholar
• Short H, Stafinski T, Menon D, et al. Approach to reimbursement decision-making on drugs for rare diseases in Canada? Insights from across the ponds. Healthc Policy. 2015 May;10(4):24–46.
   PubMedGoogle Scholar
• Taylor C, Jan S, Thompson K. Funding therapies for rare diseases: an ethical dilemma with a potential solution. Aust Health Rev. 2018 Feb;42(1):117–119.
   PubMed Web of Science ®Google Scholar
• Han KT, Kim J, Nam CM, et al. Association between reduction in copayment and gastric cancer patient concentration to the capital area in South Korea: NHI cohort 2003-2013. Health Policy. 2016 Jun;120(6):580–589.
   PubMed Web of Science ®Google Scholar
• You CH, Kang S, Kwon YD, et al. Time trend of out-of-pocket expenditure among cancer inpatients: evidence from Korean tertiary hospitals. Asian Pac J Cancer Prev. 2013;14(11):6985–6989.
   PubMedGoogle Scholar
• Lee SH, Yoo SL, Bang JS, et al. Patient accessibility and budget impact of Orphan drugs in South Korea: long-term and real-world data analysis (2007-2019). Int J Environ Res Public Health. 2020 Apr 26;17(9):2991.
   PubMed Web of Science ®Google Scholar
• Lee JH. Pricing and reimbursement pathways of new Orphan drugs in South Korea: a longitudinal comparison. Healthcare (Basel). 2021 Mar 8;9(3):296.
   PubMedGoogle Scholar
• An J, Kim S. Medical cost trends under national health insurance benefit extension in Republic of Korea. Int J Health Plann Manage. 2020 Nov;35(6):1351–1370.
   PubMed Web of Science ®Google Scholar
• Copayment reduction for patients with severe disease and rare·severe incurable disease [Internet]. Sejong: Ministry of Health and Welfare. [updated 2021 Oct 26; cited 2022 Dec 2]. Available from: https://www.mohw.go.kr/react/policy/index.jsp?PAR_MENU_ID=06&MENU_ID=06350307&PAGE=7&topTitle
   Google Scholar
• Criteria for co-payment reduction of partial out-of-pocket [Internet]. Sejong: Ministry of Health and Welfare. [cited 2023 Feb 3]. Available from: https://www.law.go.kr/%ED%96%89%EC%A0%95%EA%B7%9C%EC%B9%99/%EB%B3%B8%EC%9D%B8%EC%9D%BC%EB%B6%80%EB%B6%80%EB%8B%B4%EA%B8%88%20%EC%82%B0%EC%A0%95%ED%8A%B9%EB%A1%80%EC%97%90%20%EA%B4%80%ED%95%9C%20%EA%B8%B0%EC%A4%80
   Google Scholar
• Detailed evaluation criteria for drugs subject to negotiation, such as new drugs [Internet]. Wonju: Health Insurance Review and Assessment Service. [cited 2023 Feb 2]. Available from: https://biz.hira.or.kr/index.do?sso=ok
   Google Scholar
• Regulations on evaluation standards and procedures for whether drugs are eligible for medical care expenses [Internet]. Wonju: Health Insurance Review and Assessment Service. [updated 2018 Jun 1; cited 2023 Feb 3]. Available from: https://www.law.go.kr/LSW/schlPubRulInfoP.do?schlPubRulId=2117355&efYd=&schlPubRulNm=%EC%95%BD%EC%A0%9C%EC%9D%98%20%EC%9A%94%EC%96%91%EA%B8%89%EC%97%AC%EB%8C%80%EC%83%81%EC%97%AC%EB%B6%80%20%EB%93%B1%EC%9D%98%20%ED%8F%89%EA%B0%80%EA%B8%B0%EC%A4%80%20%EB%B0%8F%20%EC%A0%88%EC%B0%A8%20%EB%93%B1%EC%97%90%20%EA%B4%80%ED%95%9C%20%EA%B7%9C%EC%A0%95
   Google Scholar
• Notification of partial revision of regulations on designation of orphan drugs [Internet]. Cheongju: Ministry of Food and Drug Safety. [cited 2022 Dec 3]. Available from: https://www.mfds.go.kr/brd/m_207/list.do?page=1&srchFr=&srchTo=&srchWord=%ED%9D%AC%EA%B7%80%EC%9D%98%EC%95%BD%ED%92%88&srchTp=0&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&Data_stts_gubun=C9999
   Google Scholar
• Notification of Orphan drug designation [Internet]. Cheongju: Ministry of Food and Drug Safety. [updated 2022 Mar 7; cited 2022 Dec 23]. Available from: https://www.mfds.go.kr/brd/m_76/list.do?page=2&srchFr=&srchTo=&srchWord=%ED%9D%AC%EA%B7%80%EC%9D%98%EC%95%BD%ED%92%88&srchTp=0&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&Data_stts_gubun=C9999
   Google Scholar
• Information search for medicines [Internet]. Cheongju: Ministry of Food and Drug Safety. [ cited 2023 Feb 3]. Available from: https://nedrug.mfds.go.kr/searchDrug
   Google Scholar
• Reimbursement record information [Internet]. Wonju: Health Insurance Review and Assessment Service. [cited 2023 Feb 2]. Available from: https://www.hira.or.kr/ra/medi/getHistoryList.do?pgmid=HIRAA030035020000
   Google Scholar
• Stafinski T, Glennie J, Young A, et al. HTA decision-making for drugs for rare diseases: comparison of processes across countries. Orphanet J Rare Dis. 2022;17(1):258.
   PubMed Web of Science ®Google Scholar
• Postma MJ, Noone D, Rozenbaum MH, et al. Assessing the value of orphan drugs using conventional cost-effectiveness analysis: is it fit for purpose? Orphanet J Rare Dis. 2022;17(1):157.
   PubMed Web of Science ®Google Scholar
• Varley Á, Tilson L, Fogarty E, et al. The utility of a rapid review evaluation process to a national HTA agency. Pharmacoeconomics. 2022 Feb;40(2):203–214.
   PubMed Web of Science ®Google Scholar
• Blonda A, Denier Y, Huys I, et al. How to value Orphan drugs? A review of European value assessment frameworks. Front Pharmacol. 2021;12:631527.
   PubMed Web of Science ®Google Scholar
• Criteria for drug determination and adjustment [Internet]. Sejong: Ministry of Health and Welfare. [cited 2023 Feb 3]. Available from: https://www.law.go.kr/LSW/admRulLsInfoP.do?admRulSeq=2100000215259
   Google Scholar